Credit Suisse’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Credit Suisse’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-79,251	Closed	-$800K	–	3946
2022 Q4	$800K	Buy	+79,251	New	+$793K	﹤0.01%	2494

Credit Suisse's BIOT Position: Q1 2023 in Review

Credit Suisse sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 79,251 shares — an estimated $800K sold.

Credit Suisse first reported a position in BIOT in Q4 2022 and held it in 1 quarter. The position peaked at $800K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Credit Suisse reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 79,251 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $800K.
Credit Suisse first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2022 and held it in 1 quarter.
Credit Suisse's Biotech Acquisition Company Class A Ordinary Shares position peaked at $800K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.